Randomized Trial of Unmanipulated Mobilized Blood/Marrow Versus Blood Haploidentical Transplant With Standard-risk Leukemia
2 Years
60 Years
Both
Leukemia
Trial Information
Randomized Trial of Unmanipulated Mobilized Blood/Marrow Versus Blood Haploidentical Transplant With Standard-risk Leukemia
The donors were primed with granulocyte-colony stimulating factor (G-CSF) injected
subcutaneously for five consecutive days. In the trial group, the PBSCs were harvested on
the fourth and fifth day;in the control group, the bone marrow cells were harvested on the
fourth day and the PBSCs were harvested on the fifth day.
Inclusion Criteria:
- Standard risk of Recipients of haploidentical stem cell transplantation with
myeloablative conditioning regimens
Exclusion Criteria:
- Active, uncontrolled infection
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label
Outcome Measure:
incidence of engraftment
Outcome Description:
number of participants with engraftment at 30d
Outcome Time Frame:
paticipants will be followed for the duration of hospital stay,an expected average of 30 days
Safety Issue:
No
Principal Investigator
Xiao-Jun Huang, M.D.
Investigator Role:
Principal Investigator
Investigator Affiliation:
Peking University People's Hospital
Authority:
China: Ministry of Health
Study ID:
PUPH IRB [2012] (27)
NCT ID:
NCT01617473
Start Date:
December 2013
Completion Date:
December 2015
Related Keywords:
- Leukemia
- Leukemia
Name | Location |
|---|
